|1.||Moss, Donald E: 3 articles (05/2013 - 03/2005)|
|2.||Sumaya, Isabel C: 2 articles (08/2005 - 03/2005)|
|3.||Braglia, Enrico: 1 article (05/2013)|
|4.||Pericle, Federica: 1 article (05/2013)|
|5.||Fariello, Ruggero G: 1 article (05/2013)|
|6.||Sumaya, Isabel: 1 article (05/2013)|
|7.||Sahlmann, Jörg: 1 article (05/2013)|
|8.||Byers, Donna M: 1 article (08/2005)|
|9.||Irwin, Louis N: 1 article (08/2005)|
|10.||Hohmann, Christine F: 1 article (08/2005)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/1999 - "Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type."
03/15/2005 - "Methanesulfonyl fluoride (MSF), a highly selective CNS inhibitor of acetylcholinesterase, has been recently demonstrated to promote improvement in cognitive performance in patients with senile dementia of Alzheimer type. "
05/01/2013 - "A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease."
08/08/2005 - "Methanesulfonyl fluoride (MSF) is a CNS-selective acetylcholinesterase (AChE) inhibitor, currently being developed and tested for the treatment of symptoms of Alzheimer's disease. "
01/01/1999 - "The purpose of the present study was to evaluate methanesulfonyl fluoride (MSF), a very long-acting CNS-selective acetylcholinesterase (AChE) inhibitor, as a palliative treatment for senile dementia of the Alzheimer type (SDAT). "
|2.||Memory Disorders (Memory Loss)
10/01/1999 - "After treatment with methanesulfonyl fluoride (a lipid-soluble anticholinesterase), which reduced their AChE activity by >90%, these muscles were subjected to an in situ indirect stimulation protocol, including a series of isolated twitch and tetanic contractions preceding a 3-min fatigue regimen (100-ms trains at 75 Hz applied every 1.5 s). "
|4.||Amnesia (Dissociative Amnesia)
|1.||Palliative Care (Palliative Medicine)